Burning Rock Biotech (NASDAQ: BNR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-30 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.390 | -0.0300 | ||||
REV | 20.810M | 21.379M | 569.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Burning Rock Biotech (NASDAQ: BNR) through any online brokerage.
Other companies in Burning Rock Biotech’s space includes: Humacyte (NASDAQ:HUMA), Precigen (NASDAQ:PGEN), bluebird bio (NASDAQ:BLUE), Adaptimmune Therapeutics (NASDAQ:ADAP) and Mesoblast (NASDAQ:MESO).
The latest price target for Burning Rock Biotech (NASDAQ: BNR) was reported by CICC on Wednesday, July 14, 2021. The analyst firm set a price target for 39.94 expecting BNR to rise to within 12 months (a possible 1401.50% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Burning Rock Biotech (NASDAQ: BNR) is $2.66 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Burning Rock Biotech.
Burning Rock Biotech’s Q2 earnings are confirmed for Tuesday, August 30, 2022.
There is no upcoming split for Burning Rock Biotech.
Burning Rock Biotech is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.